SAB Biotherapeutics, Inc. (SABS) NASDAQ
3.90
+0.15(+4.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.90
+0.15(+4.00%)
Currency In USD
Address
2100 East 54th Street North
Sioux Falls, SD 57104
United States of America (the)
Phone
605 679 6980
Sector
Healthcare
Industry
Biotechnology
Employees
63
First IPO Date
February 09, 2021
| Name | Title | Pay | Year Born |
| Samuel J. Reich | Chairman & CEO | 782,100 | 1975 |
| Lucy To | Executive VP & CFO | 380,659 | 1986 |
| Christoph Bausch | Executive Vice President & Chief Operating Officer | 574,585 | 1971 |
| Eddie Joe Sullivan | Co-Founder, President & Director | 744,382 | 1966 |
| Alexandra Kropotova | Executive VP & Chief Medical Officer | 790,150 | 1972 |
| Carlos N. Carillo | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Angie Parizek | Senior Vice President of Clinical Operations | 0 | N/A |
| Catherine DeRose | Vice President of Human Resources | 0 | N/A |
| Hua Wu | Senior Vice President of Product Development | 0 | N/A |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.